ECSP024392A - GLUCAGON TYPE-1 PEPTIDE ANALOGS - Google Patents
GLUCAGON TYPE-1 PEPTIDE ANALOGSInfo
- Publication number
- ECSP024392A ECSP024392A ECSP024392A ECSP024392A EC SP024392 A ECSP024392 A EC SP024392A EC SP024392 A ECSP024392 A EC SP024392A EC SP024392 A ECSP024392 A EC SP024392A
- Authority
- EC
- Ecuador
- Prior art keywords
- glp
- glu
- asp
- ala
- lys
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto GLP-1 que comprende la secuencia de aminoácidos de fórmula 1 (SEQ ID No. 1) His-Xaa8-Glu-Gly-Xaa11-Xaa12-Thr-Ser-asp-Xaa16-Ser-Ser-Tyr-Leu-Glu-Xaa22-Xaa23-Xaa24-Ala-Xaa27-Phe-Ile-Ala-Xaa31-Leu-Xaa33-Xaa34-Xaa35-Xaa36-R . Fórmula I (SEQ ID No:1) en la que: Xaa8 es: Gly, Ala, Val, Leu, Ile, Ser o Thr; Xaa11 es: Asp, Glu, Arg, Thr, Ala, Lys o His; Xaa12 es: His, Trp, Phe o Tyr; Xaa16 es: Leu, Ser, Thr, Trp, His, Phe, Asp, Val, Tyr, Glu, o Ala; Xaa22 es: Gly, Asp, Glu, Gln, Asn, Lys, Arg, Cys o ácido cisteico; Xaa23 es: His, Asp, Lys, Glu, Gln o Arg; Xaa24 es: Glu, Arg, Ala o Lys; Xaa26 es; Trp, Tyr, Phe, Asp, Lys, Glu o His; Xaa27 es: Ala, Glu, His, Phe, Tyr, Trp, Arg o Lys; Xaa30 es: Ala, Glu, Asp, Ser o His; Xaa33 es: Asp, Arg, Val, Lys, Ala, Gly o Glu; Xaa34 es: Glu, Lys o Asp; Xaa35 es: Tbr, Ser, Lys, Arg, Trp, Tyr, Phe, Asp, Gly, Pro, His o Glu; Xaa36 es: Tbr, Ser, Asp, Trp, Tyr, Phe, Arg, Glu o His; R es: Lys, Arg, Tbr, Ser, Glu, Asp, Txp, Tyr, Phe, His, - NH2, Gly, Gly-Pro o Gly-Pro-Nh2 o no aparece. con la condición de que el compuesto GLP-1 no tenga la secuencia de GLP-1 (7-37) OH o GLP-1 (7-36) NH2 y, con tal de que el compuesto GLP-1 no sea Gly8-GLP.-1(7-37)OH, Gly8-GLP-1(7-36)NH2, Val8-GLP1-(7-37)OHM Leu8-GLP-1(7-36)NH2, Ile8-GLP-1(7-37)OH, Ile8-GLP-1(7-36NH2, Ser8- GLP-1(7-37)OH,Ser8-GLP1(7-36)NH2, Thr8-GLP-1(7-37)OH,o Thr8-GLP-1-(7-36)nh2, aLA11-glp-1(7-37)oh, aLA11-glp-1(7-36)NH2, Ala 16-GLP-1(7-37) OH, Ala16-GLP-1(7-36)NH2M ALA18-GLP-1(7-37)OH, Ala 18-GLP-1(7-36)NH2, Ala 27-GLP-1/7-37)OH, Ala27,-GLP-1(7-36)NH2, Ala33-GLP-(7-37) OH, Ala33-GLP-1(7-36NH2.A GLP-1 compound comprising the amino acid sequence of formula 1 (SEQ ID No. 1) His-Xaa8-Glu-Gly-Xaa11-Xaa12-Thr-Ser-asp-Xaa16-Ser-Ser-Tyr-Leu-Glu -Xaa22-Xaa23-Xaa24-Ala-Xaa27-Phe-Ile-Ala-Xaa31-Leu-Xaa33-Xaa34-Xaa35-Xaa36-R. Formula I (SEQ ID No: 1) in which: Xaa8 is: Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa11 is: Asp, Glu, Arg, Thr, Ala, Lys or His; Xaa12 is: His, Trp, Phe or Tyr; Xaa16 is: Leu, Ser, Thr, Trp, His, Phe, Asp, Val, Tyr, Glu, or Ala; Xaa22 is: Gly, Asp, Glu, Gln, Asn, Lys, Arg, Cys or cysteic acid; Xaa23 is: His, Asp, Lys, Glu, Gln or Arg; Xaa24 is: Glu, Arg, Ala or Lys; Xaa26 is; Trp, Tyr, Phe, Asp, Lys, Glu or His; Xaa27 is: Ala, Glu, His, Phe, Tyr, Trp, Arg or Lys; Xaa30 is: Ala, Glu, Asp, Ser or His; Xaa33 is: Asp, Arg, Val, Lys, Ala, Gly or Glu; Xaa34 is: Glu, Lys or Asp; Xaa35 is: Tbr, Ser, Lys, Arg, Trp, Tyr, Phe, Asp, Gly, Pro, His or Glu; Xaa36 is: Tbr, Ser, Asp, Trp, Tyr, Phe, Arg, Glu or His; R is: Lys, Arg, Tbr, Ser, Glu, Asp, Txp, Tyr, Phe, His, - NH2, Gly, Gly-Pro or Gly-Pro-Nh2 or does not appear. with the proviso that the GLP-1 compound does not have the sequence of GLP-1 (7-37) OH or GLP-1 (7-36) NH2 and, provided that the GLP-1 compound is not Gly8-GLP .-1 (7-37) OH, Gly8-GLP-1 (7-36) NH2, Val8-GLP1- (7-37) OHM Leu8-GLP-1 (7-36) NH2, Ile8-GLP-1 ( 7-37) OH, Ile8-GLP-1 (7-36NH2, Ser8-GLP-1 (7-37) OH, Ser8-GLP1 (7-36) NH2, Thr8-GLP-1 (7-37) OH, or Thr8-GLP-1- (7-36) nh2, aLA11-glp-1 (7-37) oh, aLA11-glp-1 (7-36) NH2, Ala 16-GLP-1 (7-37) OH , Ala16-GLP-1 (7-36) NH2M ALA18-GLP-1 (7-37) OH, Ala 18-GLP-1 (7-36) NH2, Ala 27-GLP-1 / 7-37) OH, Ala27, -GLP-1 (7-36) NH2, Ala33-GLP- (7-37) OH, Ala33-GLP-1 (7-36NH2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21217100P | 2000-06-16 | 2000-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP024392A true ECSP024392A (en) | 2003-02-06 |
Family
ID=32849305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP024392 ECSP024392A (en) | 2000-06-16 | 2002-12-13 | GLUCAGON TYPE-1 PEPTIDE ANALOGS |
Country Status (3)
Country | Link |
---|---|
EC (1) | ECSP024392A (en) |
UA (1) | UA88862C2 (en) |
ZA (1) | ZA200210098B (en) |
-
2001
- 2001-06-01 UA UA20021210090A patent/UA88862C2/en unknown
-
2002
- 2002-12-12 ZA ZA200210098A patent/ZA200210098B/en unknown
- 2002-12-13 EC ECSP024392 patent/ECSP024392A/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200210098B (en) | 2004-03-12 |
UA88862C2 (en) | 2009-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR031701A1 (en) | COMPOUNDS ANA LOGOS OF (GLP-1) -PEPTIDE-1 GLUCAGON ANALOG, METHOD FOR STIMULATING GLP-1 RECEPTORS USING SUCH COMPOUNDS AND USING SUCH COMPOUNDS IN THE PREPARATION OF MEDICINES TO STIMULATE THE INSULIN SECRETION | |
AR038102A1 (en) | GLUCAGON TYPE 1 PEPTIDE EXTENDED ANALOGS | |
JP2008500281A5 (en) | ||
JP2019504057A5 (en) | ||
CA2320371A1 (en) | Inotropic and diuretic effects of exendin and glp-1 | |
CA2277112C (en) | Use of exendins and agonists thereof for the reduction of food intake | |
CA2309356A1 (en) | Novel exendin agonist compounds | |
RU2009126634A (en) | Peptide pharmaceutical compositions and drugs on its base, method of treatment and / or prevention of diabetes or a condition associated with obesity, a method of reducing appetite, reduced food intake, a decrease in caloric intake, a decrease in body weight and increase in costs ENERGY | |
CA2310097A1 (en) | Novel exendin agonist compounds | |
ES2614603T3 (en) | GLP-1 Molecule Administration Procedure | |
US1315215A (en) | Rifle-stock. | |
CL2021000158A1 (en) | Gip / glp1 coagonist compounds | |
JP2009529553A5 (en) | ||
WO2019085772A1 (en) | Treatment of biliary cirrhosis based on oxyntomodulin analogue glp-1r/gcgr dual-target agonist peptide | |
CA2299425A1 (en) | Novel exendin agonist compounds | |
CA2048910A1 (en) | Antimicrobial peptides active against plant pathogens, their method of use and various screening methods pertaining thereto | |
W. POTTS et al. | The effects of hypophysectomy and bovine prolactin on salt fluxes in fresh-water-adapted Fundulus heteroclitus | |
PE20230861A1 (en) | LONG-ACTING GLP-1/GIP DOUBLE AGONISTS | |
ECSP024392A (en) | GLUCAGON TYPE-1 PEPTIDE ANALOGS | |
AR047776A1 (en) | GLP PHARMACEUTICAL COMPOSITIONS - 1 | |
CO2020012425A2 (en) | Novel analogs of glp-1 | |
UA102370C2 (en) | Peptide, pharmaceutical composition and medicament comprising thereof, method for the treatment and/or prevention of diabetes and diseases associated with obesity, method for reduction in appetite, reduction in food intake or reduction of calorie intake | |
ATE332921T1 (en) | NEW PEPTIDE COMPOSITIONS AND THE USE THEREOF, IN PARTICULAR FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS ACTIVE AGAINST THE HEPATITIS C VIRUS | |
Holst | Glucagon-like peptide-1: physiology and therapeutic potential | |
US3628519A (en) | Demountable archery bow |